Sekisui XenoTech Provides Genotyped Hepatocytes for Polymorphic Enzyme Drug Metabolism Studies

Genotyped hepatocytes pooled to study the effects of specific genetic variants on drug metabolism and transport to identify risks of adverse drug interactions present only in genetically-defined subpopulations of patients.

KANSAS CITY, KS, UNITED STATES - Apr 12, 2016 - Sekisui XenoTech now offers Geneknown pooled human hepatocytes as part of its catalog of cell and tissue-based products. Geneknown hepatocytes are pools of cryopreserved cells from multiple donors assembled to study the effects of specific genetic variants on drug metabolism and transport in human hepatocytes in vitro.

Drug metabolism studies conducted with Geneknown pooled human hepatocytes can identify risks of adverse drug interactions present only in genetically-defined subpopulations of patients. Such risks can remain undetected when pooled hepatocytes representing multiple genotypes are utilized.

Thirty pharmacogenetically-relevant genes were evaluated for the presence of significant alleles and SNPs (single nucleotide polymorphisms). A full list of the alleles and SNP IDs comprising the characterization of Geneknown hepatocytes can be found on Sekisui XenoTechs website.

Highlights of Geneknown pooled human hepatocytes include:

Cells were cryopreserved with a patent pending single-freeze process for high viability and cell yield
CYP2C19*2/*2 no activity homozygotes and CYP2C19*1/*1 wild-type controls
Complex genetics of CYP2D gene cluster are characterized with 25 individual SNP assays, as well as, CYP2D6 and CYP2D7 gene copy number variation assays, allowing identification of ultra-rapid, extensive and poor metabolizers
CYP3A5*1/*1 high-activity homozygotes, CYP3A5*1/*3 intermediate activity heterozygotes and CYP3A5*3/*3 no-activity control cells
UGT1A1 low-activity donors carrying two alleles of reduced activity and wild-type UGT1A1*1/*1 control donors
OATP1B1*5/*5 homozygotes and wild-type OATP1B1*1/*1 control cells

Genotyped human liver microsomes are also available from Sekisui XenoTech, and genotyped hepatocytes from individual donors may be provided upon custom request. Learn more at www.xenotech.com/products.

About Sekisui XenoTech
Sekisui XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. Sekisui XenoTech's product selection includes a wide-range of high quality standard reagents, from subcellular fractions and hepatocytes to recombinant enzymes, substrates and metabolites. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company's website at www.xenotech.com or call your local Sekisui XenoTech representative.